Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

Delayed Quote. Delayed  - 11/23 04:24:14 pm
4990 ILa   +4.61%
05:46p TEVA PHARMACEUT : Gains Amid Layoffs
11/23 TEVA PHARMACEUT : plans over 1,000 layoffs in Israel
11/23 IBI : Teva layoffs ready investors for offering
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Teva Pharmaceutical Industries : EU regulators charge Teva over pay-for-delay drug deal

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/17/2017 | 01:36pm CET
A building belonging to Teva Pharmaceutical Industries, the world's biggest generic drugmaker and Israel's largest company, is seen in Jerusalem

EU antitrust regulators charged Israeli drugmaker Teva (>> Teva Pharmaceutical Industries Limited) on Monday with doing an illegal deal with Cephalon to delay selling a cheaper generic version of the latter's sleep disorder drug, putting it at risk of a fine.

EU antitrust regulators charged Israeli drugmaker Teva (>> Teva Pharmaceutical Industries Limited) <TEVA.N> on Monday with doing an illegal deal with Cephalon to delay selling a cheaper generic version of the latter's sleep disorder drug, putting it at risk of a fine.

The crackdown by the European Commission follows fines against scores of companies including Denmark's Lundbeck, U.S. giant Johnson & Johnson and France's Servier in recent years over similar deals.

The EU competition enforcer's 2009 inquiry into the sector showed that so-called pay-for-delay deals cost European consumers billions of euros.

Teva, the world's biggest generic drugmaker, reached the deal with Cephalon as part of a settlement to end a lawsuit over alleged infringement of Cephalon's patents on the blockbuster drug. This involved cash payments from Cephalon, which Teva later acquired in 2011.

The Commission said the deal may have pushed up prices of the drug, modafinil.

"The patent settlement agreement between Cephalon and Teva may have caused substantial harm to EU patients and health service budgets," the EU competition enforcer said in a statement.

Teva said it strongly disagreed with the Commission's analysis on such deals.

"We do not believe that Cephalon and Teva entered into any anti-competitive behavior," the company said.

Teva, which can ask for a closed-door hearing to defend its case, can be fined up to 10 percent of its global turnover if found guilty of breaching EU antitrust rules. The company made $21.9 billion of revenue in 2016.

It was fined 15.6 million euros ($17.9 million) in 2014 for an illegal deal with Servier.

The Commission in May sent a warning shot to the sector by opening an investigation into alleged excessive pricing by South Africa's Aspen Pharmacare (>> Aspen Pharmacare Holdings Limited) for five cancer medicines.

(Reporting by Foo Yun Chee; Additional reporting by Ari Rabinovitch in Jerusalem; Editing by Philip Blenkinsop and Mark Potter)

By Foo Yun Chee

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TEVA PHARMACEUTICAL INDUST
05:46p TEVA PHARMACEUTICAL INDUSTRIES : Gains Amid Layoffs
11/23 TEVA PHARMACEUTICAL INDUSTRIES : plans over 1,000 layoffs in Israel
11/23 IBI : Teva layoffs ready investors for offering
11/18DJADRs End Higher; JA Solar, NetEase Trade Actively
11/16 TEVA PHARMACEUTICAL INDUSTRIES : Tel Aviv District Court Ordered MediWound to Pu..
11/15 TEVA PHARMACEUTICAL INDUSTRIES : Announces Prescription Copay Savings Program fo..
11/15 TEVA PHARMACEUTICAL INDUSTRIES : Allergan begins selling 10% Teva stake to JP Mo..
11/15 TEVA PHARMACEUTICAL INDUSTRIES : Tel Aviv District Court Ordered MediWound to Pu..
11/14 TEVA PHARMACEUTICAL INDUSTRIES : Allergan begins selling 10% Teva stake to JP Mo..
11/14 TEVA PHARMACEUTICAL INDUSTRIES : George Horesh mulls buying Ra'anana land back f..
More news
News from SeekingAlpha
12:34p Teva Pharmaceutical goes ex-dividend on Monday
10:59a YOUR DAILY PHARMA SCOOP : Bioverativ Worth A Look, Teva Announces Workforce Cut,..
06:51a WALL STREET BREAKFAST : Black Friday In Full Swing
02:40a Struggling Teva Announces Mass Layoffs
11/23 Massive layoffs coming to Teva
Financials ($)
Sales 2017 22 633 M
EBIT 2017 6 276 M
Net income 2017 -
Debt 2017 34 419 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 2,16x
EV / Sales 2018 2,05x
Capitalization 14 431 M
Chart TEVA PHARMACEUTICAL INDUST
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Technical analysis trends TEVA PHARMACEUTICAL INDUST
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 28,0 $
Spread / Average Target 97%
Managers
NameTitle
Kåre Schultz President, Chief Executive Officer & Director
Sol J. Barer Chairman
Carlo de Notaristefani President & CEO-Global Operations
Michael McClellan Chief Financial Officer
Michael R. Hayden Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED-64.38%14 431
JOHNSON & JOHNSON19.17%368 832
NOVARTIS12.82%222 846
ROCHE HOLDING LTD.6.15%216 979
PFIZER9.08%211 188
MERCK AND COMPANY-7.64%148 286